FR Doc E6-14050 [Federal Register: August 24, 2006 (Volume 71, Number 164)] [Notices] [Page 50097-50099] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr24au06-77]

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Peter A. Ahles, M.D.; Revocation of Registration

On August 15, 2005, I, the Deputy Administrator of the Drug Enforcement Administration, issued an Order to Show Cause and further ordered the immediate suspension of DEA Certificate of Registration, AA0092558, issued to Peter A. Ahles, M.D. (Respondent), of Anaheim, California. The Show Cause Order proposed to revoke Respondent's registration as a practitioner and to deny any pending applications for renewal or modification of the registration, on the ground that Respondent's continued registration would be inconsistent with the public interest. See 21 U.S.C. 823(f) and 824(a)(4). The Show Cause Order also immediately suspended Respondent's registration based on my preliminary finding that his continued registration "would constitute an immediate danger to the public health and safety because of the substantial likelihood that [he would] continue to acquire large amounts of narcotic controlled substances and * * * illegally distribute these narcotic controlled substances to potential abusers and other unauthorized persons in exchange for cash." Show Cause Order at 3. 

The Show Cause Order specifically alleged that based on a review of transaction reports filed by DEA registrants, Respondent, during the period March 2004 to March 2005, had received "nearly 570,000 tablets of Schedule III hydrocodone and codeine tablets, most of which were packaged in 500 and 1000 count bottles." Id. at 1-2. The Show Cause Order alleged that "[t]hese are excessive amounts of narcotics to be legitimately dispensed or administered from a single practitioner's office in a one-year period." Id. The Show Cause Order further alleged that in the thirteen month period ending in April 2005, Respondent "had purchased over one million dosage units of Schedule II through V controlled substances, [which were] predominately narcotic tablets." Id. at 2. 

The Show Cause Order also alleged that on three occasions during May 2005, a DEA Special Agent and a cooperating source (CS) had visited Respondent's office and made undercover buys of hydrocodone, a Schedule III controlled substance. Id. The Show Cause Order alleged that on two occasions, the Special Agent observed the CS pay Respondent $500 in cash and receive a plastic bag containing approximately 500 tablets of hydrocodone. Id. The Show Cause Order alleged that on the other occasion, the Special Agent observed the CS pay Respondent $600 and receive a plastic bag containing 500 tablets of Norco, another hydrocodone product. Id. The Show Cause Order further alleged that Respondent made each of the dispensings without asking the CS for his medical complaint, taking a medical history, or conducting a physical examination. The Show Cause Order thus alleged that the distributions were made "without any legitimate medical purpose and [were] not in the course of legitimate medical practice" and violated 21 U.S.C. 841(a)(1). Id. 

Finally, the Show Cause Order alleged that Respondent had, in submitting his DEA renewal application, answered

[[Page 50098]]

"No" the question whether his state license had ever been revoked, suspended, or placed on probation. Id. The Show Cause Order alleged that the Medical Board of California had, in fact, placed Respondent's state license on probation three different times and that Respondent had thus "materially falsified [his] application for registration in violation of 21 U.S.C. 843(a)(4)(A)." Id. at 2-3. Based on evidence in the investigative file supporting the above allegations, I further made the preliminary finding that Respondent had "grossly avoided [his] responsibilities as a registrant and [had] been responsible for the actual diversion of controlled substances into other than legitimate channels in violation of 21 U.S.C. 841(a)(1)."¹

On August 16, 2005, a DEA Diversion Investigator (DI) personally served the Show Cause Order on Respondent. Since that time, neither Respondent, nor anyone purporting to represent him, has responded. Because (1) more than thirty days have passed since Respondent's receipt of the Show Cause Order, and (2) no request for a hearing has been received, I conclude that Respondent has waived his right to a hearing. See 21 CFR 1309.53(c). I therefore enter this final order without a hearing based on information contained in the investigative file.

Findings

Respondent is the holder of DEA Certificate of Registration No. AA0092588, which expired on June 30, 2005. On May 5, 2005, Respondent applied for a renewal of his registration and sought authority to prescribe Schedule II through V controlled substances including Schedule II and III narcotics. On his renewal application, Respondent answered "No" the question: "Has the applicant ever surrendered (for cause) or had a state professional license or controlled substance registration revoked, suspended, denied, restricted, or placed on probation?" 

According to the Medical Board of California's records, at the time Respondent filed his renewal application, he had been the subject of three separate disciplinary proceedings. In each of these cases, the California Board placed Respondent on probation.\2\ I also take official notice of the records of the California Board which indicate that on February 24, 2006, Respondent surrendered his state license.

The investigative file further establishes that between March 2004 and April 2005, Respondent purchased over one million dosage units of Schedule III through Schedule V controlled substances from ANDA Pharmaceuticals. Respondent obtained hydrocodone 7.5 and 10 mg. tablets, codeine 4, Stadol (butorphanol tartrate), and Phenergan with codeine. 

The investigative file also establishes that in April 2005, a DEA Special Agent and a DEA Diversion Investigator debriefed a cooperating source (CS). The CS stated that he/she had purchased various controlled substances including hydrocodone, Norco, and Xanax from Respondent. During the interviews, the CS related that Respondent performed little to no medical examination and did not require that the CS give a medical reason before selling the drugs to the CS. The CS further asserted that Respondent charged $500 cash for 500 pills/tablets of controlled substances, but charged $600 for 500 pills/tablets of Norco. The CS also stated that Respondent would prescribe any drug including Schedule II controlled substances such as Oxycontin to persons he knows well. Finally, the CS related that Respondent had few legitimate patients and that most of the people he saw visited him to obtain prescription drugs either for personal use or to resell the drugs on the street. 

The investigative file further establishes that following the interviews, a DEA special agent accompanied the CS to Respondent's office on three separate dates. On May 12, 2005, the Special Agent observed as the CS paid Respondent $500 and received a black plastic bag containing approximately 500 hydrocodone tablets. Respondent did not perform a physical examination on the CS and did not discuss with the CS a medical reason for the dispensing. Moreover, Respondent did not give the CS any directions for use of the drugs. The Special Agent further observed that Respondent appeared to be under the influence of some substance. 

On May 18, 2005, the same Special Agent and the CS returned to Respondent's office. On this occasion, the CS paid $600 and received from Respondent a black plastic bag containing 500 tablets of Norco. While on this occasion Respondent weighed the CS, the CS offered no medical complaint and Respondent did not perform a physical exam. Respondent also failed to give the CS any directions for use of the drugs. 

Finally, on May 19, 2005, the Special Agent and the CS returned to Respondent's office. On this occasion, the Special Agent paid Respondent $500 and requested 500 hydrocodone tablets. Respondent handed the Special Agent a black plastic bag containing approximately 500 Norco tablets. The Special Agent did not complain of any medical symptoms and Respondent did not perform a physical examination.

Discussion

As pertinent here, Section 304 of the Controlled Substances Act (CSA) provides that a registration to:

Dispense a controlled substance * * * may be suspended or revoked * * * upon a finding that the registrant-- 

(1) Has materially falsified any application filed pursuant to or required by this subchapter or subchapter II of this chapter; 

* * * * * 

(3) Has had his State license or registration suspended, revoked, or denied by competent State authority and is no longer authorized by State law to engage in the * * * distribution, or dispensing of controlled substances * * *; 

(4) Has committed such acts as would render his registration under section 823 of this title inconsistent with the public interest as determined under such section[.]

21 U.S.C. 824(a).

In this case, I conclude that each of the above provisions provide independent grounds for revoking Respondent's registration. 

First, it is clear that Respondent materially falsified his May 5, 2005 application for renewal of his registration. On that application, Respondent was asked whether he had "ever surrendered (for cause) or had a state professional license or controlled substance registration revoked, suspended, denied, restricted, or placed on probation?" (emphasis added). Respondent answered "No," notwithstanding that the Medical Board of California had placed him on probation on three separate occasions. Given that the question specifically asked Respondent whether his medical license had ever been "placed on probation," it is indisputable that Respondent's answer was a material falsification. 

The CSA requires DEA to determine whether the issuance of a registration would be consistent with the public interest. See 21 U.S.C. 823(f). The provision of truthful information on applications is absolutely essential to effectuating this statutory purpose. See 21 U.S.C. 824(a)(1); see also VI Pharmacy, Rushdi Z. Salem, 69 FR 5584, 5585 (2004); Terrance E. Murphy, M.D., 61 FR 2841, 2845 (1996). As the

[[Page 50099]]

Sixth Circuit recently observed: "Candor during DEA investigations * * * is considered by the DEA to be an important factor when assessing whether a physician's registration is consistent with the public interest." Hoxie v. DEA, 419 F.3d 477, 483 (2005). Our cases accordingly hold that "'falsification cannot be tolerated."' VI Pharmacy, 69 FR at 5585 (quoting Murphy, 61 FR at 2845) (other citation omitted). Respondent's failure to truthfully answer the question regarding prior state disciplinary actions is thus reason alone to revoke his registration. 

Respondent's drug dealing provides an additional ground for revoking his registration. Such conduct clearly constitutes acts which "render his registration * * * inconsistent with the public interest." See 21 U.S.C. 824(a)(4). Moreover, while the CSA sets forth five factors to be considered in determining the public interest, see id. Sec. 823(f), I am "not required to make findings as to all of the factors, and can give each factor the weight [I] determine[] is appropriate." Hoxie, 419 F.3d at 482; see also Morall v. DEA, 412 F.3d 165, 173-74 (D.C. Cir. 2005). Where, as here, a registrant has engaged in such egregious misconduct as drug dealing, a lengthy analysis of each of the factors is unnecessary. 

It is indisputable that Respondent did not comply with applicable State and Federal laws "relating to controlled substances" and that his conduct "threaten[s] public health and safety." 21 U.S.C. 823(f)(4) and (5). Furthermore, while the investigative file does not contain evidence establishing what action the Medical Board of California took in response to this investigation, see id. Sec. 823(f)(1), I have taken official notice of the fact that on February 24, 2006, Respondent surrendered his California medical license in response to the State Board's accusation that Respondent committed unprofessional conduct for, inter alia, violating state and federal drug laws.³ See also id. 

Sec. 824(a)(3). Thus, it is clear that Respondent "has committed such acts as would render his registration * * * inconsistent with the public interest as determined under" section 823(f). Id. Sec. 824(a)(4). The revocation of Respondent's registration is therefore necessary to protect the public interest.

Order

Accordingly, pursuant to the authority vested in me by 21 U.S.C. 823(f) and 824(a), as well as 28 CFR 0.100(b) and 0.104, I hereby order that DEA Certificate of Registration, AA0092558, issued to Peter A. Ahles, M.D., be, and it hereby is, revoked. I further order that any pending applications for renewal or modification of such registration be, and they hereby are, denied. This order is effective September 25, 2006.

Dated: August 15, 2006. 

Michele M. Leonhart,
Deputy Administrator. [FR Doc. E6-14050 Filed 8-23-06; 8:45 am]

BILLING CODE 4410-09-P

NOTICE: This is an unofficial version. An official version of these publications may be obtained directly from the Government Printing Office (GPO).